Neuropsychiatry of Parkinson’s DiseaseView this Special Issue
Review Article | Open Access
Raúl de la Fuente-Fernández, "Frontostriatal Cognitive Staging in Parkinson's Disease", Parkinson’s Disease, vol. 2012, Article ID 561046, 8 pages, 2012. https://doi.org/10.1155/2012/561046
Frontostriatal Cognitive Staging in Parkinson's Disease
Cognitive impairment and behavioural disorders are often encountered in subjects with Parkinson's disease (PD). A simple PD-related frontostriatal cognitive dysfunction (PDFCD) staging is proposed. Executive dysfunction and mental fatigue (stage I), depression/anxiety (stage IIa), apathy/pain (stage IIb), and dementia (stage III) reflect a sequential process of dopamine depletion occurring in different regions of the striatum (stages I and II) and the frontal cortex (stage III). In addition to these nonmotor manifestations present in the unmedicated (OFF) state, the PDFCD model also predicts a number of complications related to dopaminergic treatment (ON state), from impulse control disorders (stages I and IIa) to hallucinations (stage IIb) and psychosis (stage III). Although the model admittedly needs further refinements, it provides a framework for hypothesis testing and may help clinicians optimize therapeutic strategies.
Parkinson’s disease (PD) is biochemically characterized by dopamine depletion [1, 2]. Although the loss of dopamine is particularly severe in the putamen, which explains the motor manifestations of the disease, other dopaminergic projections are also affected and contribute to the development of cognitive impairment and neuropsychiatric disorders [3, 4]. Thus, some degree of executive dysfunction is a virtually constant finding in PD, even in the early stages of the disease . Apathy, depression, anxiety, and fatigue are present in one third of patients , and pain is also common . Similarly, it has been estimated that approximately one third of PD subjects end up developing dementia [3, 4]. In this review, I will use a simple model to correlate these non-motor manifestations of the disease with different stages of frontostriatal dysfunction caused by dopamine depletion sequentially occurring in different regions of the striatum and the frontal cortex [8–11].
The PD-related frontostriatal cognitive dysfunction (PDFCD) staging here proposed (Figure 1) assumes that dopamine-dependent frontostriatal functioning follows an inverted U-shaped dose-response curve (Figure 2). The PDFCD model is mostly based on neuroimaging data and clinical observations, and offers stage-specific clinical predictions off and on dopaminergic medication.
2. Dopamine Depletion and Dysfunction of Frontostriatal Loops
PD is characterized by a gradient of dopamine depletion in the striatum, with the putamen being the most affected region, followed by the dorsal caudate, and then the ventral striatum (ventral caudate and nucleus accumbens) [1, 2]. A combination of PD-specific and aging-related dopamine depletion [12, 13] determines the degree of cognitive/behavioural dysfunction.
Three major anatomical and functional frontostriatal loops are proposed to be sequentially affected in PD: first, the motor loop, which connects the supplementary motor area with the putamen; second, the cognitive loop, which connects the dorsolateral prefrontal cortex (DLPFC) with the dorsal caudate nucleus; and third, a “complex” limbic loop, with connections between the orbitofrontal cortex (OFC) and the ventral caudate nucleus, and between the anterior cingulate cortex (ACC) and the nucleus accumbens. These three functional frontostriatal loops have been well characterized both theoretically and experimentally [8–11]. In more advanced PD, the direct dopaminergic projection to the frontal cortex becomes also affected, leading to cortical dopamine depletion [14, 15]. There is evidence that the release of dopamine, at both the striatal and cortical level, facilitates loop functioning [8–11]. Alterations in the motor loop are crucial because they serve to make the clinical diagnosis, signalling that PD pathology has reached midbrain dopamine cells . However, the PDFCD model only applies to the cognitive/limbic loops and the direct dopaminergic projection to the frontal cortex.
In the early stages of PD, frontal lobe dysfunction is assumed to reflect cortical “deafferentation” in relation to striatal dopamine depletion. At later stages, cortical dopamine depletion likely contributes to frontal lobe impairment. In keeping with this notion, dementia in PD is related to the loss of dopamine cells in the medial part of the substantia nigra pars compacta  and ventral tegmental area , regions that originate direct dopaminergic projections to the cortex. Interindividual variability in the time course and degree of dopamine depletion in different striatal and frontal regions may explain the wide range of clinical manifestations encountered in PD. Although the PDFCD model is only based on striatal and frontal dopamine depletion, cortical Lewy body pathology, which typically occurs in advanced PD , will eventually contribute to the development of frank dementia [16, 19].
3. PDFCD Stage I: The Frontostriatal Cognitive Loop
3.1. Functional Analysis
The frontostriatal cognitive loop (DLPFC—dorsal caudate nucleus) is involved in executive function . Normal performance of typical cognitive frontal lobe tasks, such as the Wisconsin Card Sorting Task or the Tower of London planning task, depends upon several frontal executive functions including working memory, attention, planning, and cognitive flexibility, all of them pertaining to this frontostriatal loop [20–23]. PD subjects off medication have impaired task set-shifting [24, 25], reduced basal ganglia activation during performance of the Tower of London test [26, 27], and show correlations between the degree of impairment on executive tasks and the degree of dopaminergic hypofunction in the caudate nucleus [28, 29]. These alterations are virtually constant in PD and suggest frontal lobe “deafferentation” caused by dopamine depletion in the dorsal caudate nucleus [24, 30]. There is some indication that such a “deafferentation” predicts incident dementia . Interestingly, the direct dopaminergic projection to the prefrontal cortex seems to be hyperactive early in the course of the disease [32, 33], presumably as a compensatory mechanism (Figure 2). Nonetheless, dorsal caudate-dependent tasks are consistently associated with DLPFC hypoactivation .
3.2. Clinical Correlates
3.2.1. OFF Dopaminergic Treatment
Clinical manifestations of frontal lobe dysfunction, including poor planning, defects in set-shifting, impaired working memory, and executive dysfunction, are common in PD without dementia  and correlate with a PD-related cognitive pattern of altered glucose metabolism . This pattern is characterized by metabolic reductions in frontal areas, and relative metabolic increases, presumably compensatory, in the cerebellum. Fatigue (mental fatigue) can be present in PDFCD stage I (Figures 1 and 2) and may even precede the onset of motor symptoms .
3.2.2. ON Dopaminergic Treatment
Dopaminergic treatment induces impulse control disorders (ICDs) in a number of PD subjects as the result of the overactivation of the “complex” frontostriatal limbic loop . Hence, ICDs occur in PDFCD stages I and IIa (Figure 2; see next section for further details). In contrast to the dopaminergic projections to the striatum, the activity of the dopaminergic projection to the frontal cortex is not expected to be substantially altered by dopaminergic treatment, especially when it is overactive, because it lacks dopamine transporter sites and dopamine D2 autoreceptors . In fact, the action of dopamine in the frontal cortex is mostly mediated by dopamine D1 receptors . This might explain some of the clinical differences between levodopa therapy and treatment with direct dopamine agonists. While levodopa-derived dopamine stimulates D1 and D2 receptors, dopamine agonists predominantly stimulate D2 receptors.
4. PDFCD Stage II: The “Complex” Frontostriatal Limbic Loop
4.1. Functional Analysis
In PD, the damage to the dopaminergic projection to the ventral striatum (ventral caudate and nucleus accumbens) is less prominent than the damage to the dopaminergic projection to the dorsal striatum (putamen and dorsal caudate) [1, 12]. Still, ventral regions of the striatum also undergo substantial dopamine depletion (~60% dopamine loss) [1, 13].
Reversal learning tasks, which basically test for balance between “go” and “no-go” signals , are used to assess the “complex” frontostriatal limbic loop (OFC/ACC—ventral caudate/nucleus accumbens) . As one would predict according to the regional differences in the degree of striatal dopamine depletion, PD subjects off medication perform much better in reversal learning tasks than in tasks involving the dorsal caudate circuitry [10, 41–43]. Conversely, dopaminergic therapy improves dorsal caudate related tasks and worsens reversal learning tasks [10, 41, 42]. This paradoxical effect of medication is probably due to the “over-dose” of a relatively normal ventral striatum [10, 42–45]. PD subjects tend to avoid negative outcomes when being off medication, and they are sensitive to positive outcomes when being on medication . In other words, dopaminergic therapy favours “go” signals over “no-go” signals.
4.2. Clinical Correlates
Although it is admittedly difficult to functionally separate the two components of the “complex” frontostriatal limbic loop, there is some suggestion that the OFC—ventral caudate circuit modulates social/emotional behaviour and the ACC—nucleus accumbens circuit mediates motivation and integrates cognitive and emotional iterative networks . Consequently, hypoactivation of the limbic loop, specifically the ACC—nucleus accumbens circuit, is expected to lead to apathy. Limbic loop hyperactivation, on the other hand, is expected to lead to impulsive behaviours.
4.2.1. OFF Dopaminergic Treatment
Depression, anxiety, and apathy are common in PD [6, 46, 47]. Apathy still needs a clear definition. Most authors would agree that it refers to a lack of motivation . In any case, it is increasingly recognized that apathy is not depression, although both disorders share a number of clinical characteristics, including psychomotor retardation, diminished interest, anergy, and lack of insight . The proof of concept for a distinction between apathy and depression came from the observation that non-PD-depressed patients treated with selective serotonin reuptake inhibitors (SSRIs) sometimes develop apathy [50, 51].
Some imaging studies suggest that depression in PD is associated with dopamine depletion in the ventral striatum  and hypoactivation of the cingulate cortex [53, 54]. However, these results may need to be reassessed in view of the increasing awareness of a distinction between depression and apathy. Recent estimates suggest that apathy is more prevalent than depression in PD [6, 47], suggesting that many patients who are assumed to have depression could have apathy instead. In non-PD patients with depression, the ACC (specifically, its subgenual portion) has been found to be hyperactive, not hypoactive [55–57]. In addition, pathological and neuroimaging observations in Alzheimer’s disease, where apathy is a very common phenomenon , indicate that there is a correlation between apathy and neurofibrillary tangles burden in the anterior cingulate cortex [58–60]. Likewise, apathy in PD correlates with reduced gray matter in the cingulate cortex . Taken together, these observations suggest that depression corresponds to PDFCD stage IIa (hypofunction of the OFC—ventral caudate circuit), and apathy corresponds to PDFCD stage IIb (hypofunction of the ACC—nucleus accumbens circuit) (Figures 1 and 2). Naturally, PDFCD stage IIb also includes hypofunction of the OFC—ventral caudate circuit, which explains why depression and apathy occur sequentially and share several clinical characteristics.
Depression is sometimes a premotor manifestation of PD but more often appears after motor symptom onset [6, 46]. The underlying neurochemical bases may differ in both scenarios. Depression occurring during the pre-motor phase of the disease probably reflects Lewy pathology in raphe nuclei and locus coeruleus, originating serotonergic and noradrenergic abnormalities . Accordingly, depression preceding PD motor symptoms should respond to conventional antidepressants, including SSRIs. Nonetheless, recent neuroimaging studies have challenged this concept by showing preserved serotonin transporter binding in the novo PD subjects . The neurochemical basis of pre-motor depression remains, therefore, unclear; dopamine dysfunction could play a role. Depression occurring at later stages, on the other hand, is likely related to dopamine depletion in the ventral caudate (PDFCD stage IIa; Figure 2). In this case, treatment is problematic. Many antidepressants, particularly SSRIs, have failed to demonstrate efficacy in PD [63, 64]. In fact, SSRIs can paradoxically precipitate apathy. Neuroimaging studies provide some clues to explain this phenomenon. In non-PD subjects with major depression, antidepressants correct ACC overactivity and there is a correlation between the degree of relative ACC overactivity at baseline and the response to antidepressants . In PD, treatment with SSRIs can lead to apathy by decreasing the activity of the ACC—nucleus accumbens circuit (i.e., SSRI-related functional transition from stage IIa to stage IIb).
Anxiety typically occurs during the motor phase of PD [6, 46]. Although other neurotransmitters are in all likelihood responsible for anxiety during the pre-motor phase of the disease, dopamine depletion in the ventral striatum seems to play a major role once the motor symptoms are established. Thus, the severity of anxiety is inversely correlated with dopamine/noradrenaline transporter binding in caudate, ventral striatum, and amygdala . Animal experiments indicate that stress is associated with decreased dopamine release in the nucleus accumbens and increased dopamine release in the medial prefrontal cortex . This observation suggests that anxiety occurs when the ACC—nucleus accumbens circuit is hypoactive and the direct dopaminergic projection to the frontal cortex is still functionally preserved (PDFCD stage IIb; Figure 2). However, PD subjects on dopaminergic therapy often present with a combination of depression and anxiety during the OFF periods, suggesting a connection between anxiety and PDFCD stage IIa. PD-related functional or pathological alterations in the amygdala , a limbic structure known to play an important role in anxiety disorders , could ultimately determine whether anxiety occurs in PDFCD stage IIa or stage IIb.
Apathy in PD is proposed to be associated with hypofunction of the ACC—nucleus accumbens circuit (PDFCD stage IIb; Figure 2). A recent study reported apathy in 23% of drug-naïve PD subjects , indicating that the limbic loop can be dysfunctional early in the course of the disease. At later stages, when PD subjects develop a combination of striatal and frontal dopamine depletion (PDFCD stage III), apathy is expected to become more prevalent and severe, with even further progression in more advanced PD, with the development of frontal Lewy body pathology [16, 19]. In this context, subjects with frontotemporal dementia have the highest prevalence rates of apathy across disorders with frontal dysfunction .
Pain is a nonmotor manifestation of PD known to be influenced by dopaminergic treatment [7, 69]. The PDFCD model suggests that pain (central pain) is related to dopamine depletion in the ventral striatum, specifically in the nucleus accumbens (PDFCD stage IIb; Figure 2). In support of this view, there is experimental evidence suggesting that the nucleus accumbens is involved in a dopamine-opioid network that modulates pain transmission [70, 71]. Pain is sometimes directly related to poor motor performance (dystonic pain) , reflecting dopamine depletion in the putamen.
It has already been mentioned that fatigue (mental fatigue) can be an early symptom of PD (PDFCD stage I) [6, 72]. More often, however, it is associated with depression and reduced motivation [6, 73], signalling PDFCD stages IIa and IIb, and possibly stage III as well. Serotonergic dysfunction may contribute to fatigue .
4.2.2. ON Dopaminergic Treatment
Remarkably, the PDFCD model suggests that depression can be present during ON periods in stages IIa and IIb (Figure 2), explaining a relatively common clinical observation (i.e., PD subjects who are depressed off and on medication).
Clinical studies suggest that some 10% of PD subjects treated with dopaminergic medications develop ICDs, including pathological gambling, compulsive shopping, compulsive eating, hypersexuality, and even addictive behaviours [75, 76]. The PDFCD model suggests that ICDs are due to treatment-related hyperactivations of the ACC—nucleus accumbens circuit, and should therefore occur in stages I and IIa (Figure 2). Experimental observations support this notion [77–79]. PD subjects with the so-called “dopamine dysregulation syndrome” (i.e., subjects with abusive use of anti-PD medication) release large amounts of dopamine in the ventral striatum after levodopa administration . It is known that the release of dopamine in the nucleus accumbens has rewarding effects , which would lead to the perpetuation of impulsive behaviours. Naturally, dopamine-related increases in the dopaminergic tone of the ventral striatum are expected to cause hyperactivation of ACC and OFC. In keeping with the PDFCD model, imaging studies in non-PD subjects with obsessive-compulsive disorder have shown decreased dopamine D2 binding—highly suggestive of increased dopamine levels—in the ventral striatum, and hyperactivation of OFC and ACC [81–84]. As the caudate nucleus modulates abnormal behaviours [5, 85], it could be tentatively argued that primarily compulsive behaviours (e.g., punding) might be more common in PDFCD stage I, and primarily reward-related ICDs (e.g., pathological gambling) might be more common in PDFCD stage IIa. In this context, ICDs in PD are associated with depression, anxiety, and obsessive-compulsive symptoms . Clinical studies suggest that young PD subjects are at high risk of developing ICDs , perhaps in relation to age-dependent dopamine release dynamics . Younger PD subjects release more dopamine, and at a faster rate, than older PD subjects.
Treatment-related visual hallucinations sometimes herald the development of dementia . The PDFCD model suggests that, by the time the first hallucinations appear, all the dopamine-dependent frontostriatal loops are already dysfunctional (hypoactive) in the OFF state, whereas the dopaminergic projection to the frontal cortex is still preserved (PDFCD stage IIb; Figure 2). In this situation, frontal dopamine levels are expected to increase in response to dopaminergic treatment (ON state), possibly explaining why visual hallucinations are associated with relative frontal hypermetabolism . Nonetheless, visual hallucinations in PD are also linked to hypometabolism in occipitotemporoparietal regions .
5. PDFCD Stage III: The Dopaminergic Projection to the Frontal Cortex
The damage to the direct dopaminergic projection to the frontal cortex signals the beginning of dementia [17, 18]. At this stage (PDFCD stage III; Figure 2), the patient begins to oscillate between dementia in the OFF state and psychosis in the ON state, a cycle that becomes more pronounced and fully established in more advanced PD, with the development of cortical Lewy body pathology. Other times, the patient remains apathetic during both OFF and ON periods.
In addition to striatal and frontal dopamine depletion, other neurotransmitters are also involved in PD dementia. Indeed, cortical cholinergic dysfunction can be even more severe in PD subjects with dementia than in patients with Alzheimer’s disease [90, 91]. In advanced PD, cortical pathology—not only Lewy bodies but also neurofibrillary tangles and amyloid deposits—becomes a major contributing factor. Thus, in vivo PET studies have found comparable levels of cortical amyloid binding in patients with dementia with Lewy bodies and patients with Alzheimer’s disease [92, 93].
The PDFCD model provides a systematic assessment of cognitive and behavioural symptoms, which may help clinicians optimize therapeutic strategies. It also provides a framework for hypothesis testing. For example, in prospective studies, apathy should not appear before ICDs in most patients. The model has a number of strengths and limitations. Among its strengths, it is simple and fits well clinical observations. For example, it explains why depression can be present during both OFF and ON periods, why depression and apathy are different disorders, and why some patients oscillate between apathy and depression or between dementia and psychosis. The combination of ON-period depression and impulsivity (PDFCD stage IIa) is relevant to explain why some PD subjects treated with subthalamic stimulation attempt suicide [94, 95]. Among its limitations, the model is in part ad hoc and does not contemplate region-specific assessments of the direct dopaminergic projection to the frontal cortex. In the early stages of PD, for example, cortical dopamine upregulation might only involve the DLPFC [32, 33]. There is evidence to suggest that the dopaminergic projection to the frontal cortex has limited capability for adaptation in response to dopaminergic treatment, particularly levodopa, due to its lack of dopamine transporter sites and dopamine D2 autoreceptors . Still, treatment-related psychosis occurring in PDFCD stage III could be associated with relative dopaminergic hyperactivity in the frontal cortex. In other words, frontal cortex “overdose” may still be possible in later stages causing psychosis. Finally, the model assumes that dopamine-dependent frontostriatal functioning follows an inverted U-shaped dose-response curve. Whereas this type of dopamine response seems to operate in the frontal cortex , it might not necessarily occur in the striatum. Additional model refinements are certainly needed, including a better definition of stages IIa and IIb. To reach this goal, we need to develop better tools to reliably distinguish between depression and apathy  and reliably measure apathy and fatigue [98, 99].
- S. J. Kish, K. Shannak, and O. Hornykiewicz, “Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications,” The New England Journal of Medicine, vol. 318, no. 14, pp. 876–880, 1988.
- O. Hornykiewicz, “Biochemical aspects of Parkinson's disease,” Neurology, vol. 51, no. 2, supplement 2, pp. S2–S9, 1998.
- B. Dubois and B. Pillon, “Cognitive deficits in Parkinson's disease,” Journal of Neurology, vol. 244, no. 1, pp. 2–8, 1997.
- D. Aarsland, K. Andersen, J. P. Larsen, A. Lolk, H. Nielsen, and P. Kragh-Sorensen, “Risk of dementia in Parkinson's disease: a community-based, prospective study,” Neurology, vol. 56, no. 6, pp. 730–736, 2001.
- J. A. Grahn, J. A. Parkinson, and A. M. Owen, “The cognitive functions of the caudate nucleus,” Progress in Neurobiology, vol. 86, pp. 141–155, 2008.
- D. Aarsland, L. Marsh, and A. Schrag, “Neuropsychiatric symptoms in Parkinson's disease,” Movement Disorders, vol. 24, no. 15, pp. 2175–2186, 2009.
- G. Defazio, A. Berardelli, G. Fabbrini et al., “Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study,” Archives of Neurology, vol. 65, no. 9, pp. 1191–1194, 2008.
- G. E. Alexander, M. R. DeLong, and P. L. Strick, “Parallel organization of functionally segregated circuits linking basal ganglia and cortex,” Annual Review of Neuroscience, vol. 9, pp. 357–381, 1986.
- S. Tekin and J. L. Cummings, “Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update,” Journal of Psychosomatic Research, vol. 53, no. 2, pp. 647–654, 2002.
- R. Cools, “Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease,” Neuroscience and Biobehavioral Reviews, vol. 30, no. 1, pp. 1–23, 2006.
- M. DeLong and T. Wichmann, “Update on models of basal ganglia function and dysfunction,” Parkinsonism and Related Disorders, vol. 15, supplement 3, pp. S237–S240, 2009.
- J. M. Fearnley and A. J. Lees, “Ageing and Parkinson's disease: substantia nigra regional selectivity,” Brain, vol. 114, no. 5, pp. 2283–2301, 1991.
- S. J. Kish, K. Shannak, A. Rajput, J. H. Deck, and O. Hornykiewicz, “Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease,” Journal of Neurochemistry, vol. 58, no. 2, pp. 642–648, 1992.
- F. Javoy-Agid and Y. Agid, “Is the mesocortical dopaminergic system involved in Parkinson disease?” Neurology, vol. 30, no. 12, pp. 1326–1330, 1980.
- B. Scatton, F. Javoy Agid, L. Rouquier, B. Dubois, and Y. Agid, “Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease,” Brain Research, vol. 275, no. 2, pp. 321–328, 1983.
- H. Braak, K. Del Tredici, U. Rüb, R. A. de Vos, E. N. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003.
- J. O. Rinne, J. Rummukainen, L. Paljarvi, and U. K. Rinne, “Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra,” Annals of Neurology, vol. 26, no. 1, pp. 47–50, 1989.
- R. M. Torack and J. C. Morris, “The association of ventral tegmental area histopathology with adult dementia,” Archives of Neurology, vol. 45, no. 5, pp. 497–501, 1988.
- R. de la Fuente-Fernández and D. B. Calne, “What do Lewy bodies tell us about dementia and parkinsonism?” in Dementia with Lewy Bodies, R. H. Perry, I. G. McKeith, and E. K. Perry, Eds., pp. 287–301, Cambridge University Press, New York, NY, USA, 1996.
- A. Dagher, A. M. Owen, H. Boecker, and D. J. Brooks, “Mapping the network for planning: a correlational PET activation study with the tower of London task,” Brain, vol. 122, no. 10, pp. 1973–1987, 1999.
- M. H. Sohn, S. Ursu, J. R. Anderson, V. A. Stenger, and C. S. Carter, “The role of prefrontal cortex and posterior parietal cortex in task switching,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 24, pp. 13448–13453, 2000.
- O. Monchi, M. Petrides, V. Petre, K. Worsley, and A. Dagher, “Wisconsin card sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging,” Journal of Neuroscience, vol. 21, no. 19, pp. 7733–7741, 2001.
- S. J. Lewis, A. Dove, T. W. Bobbins, R. A. Barker, and A. M. Owen, “Striatal contributions to working memory: a functional magnetic resonance imaging study in humans,” European Journal of Neuroscience, vol. 19, no. 3, pp. 755–760, 2004.
- R. Cools, R. A. Barker, B. J. Sahakian, and T. W. Robbins, “Mechanisms of cognitive set flexibility in Parkinson's disease,” Brain, vol. 124, no. 12, pp. 2503–2512, 2001.
- R. Cools, R. A. Barker, B. J. Sahakian, and T. W. Robbins, “Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands,” Cerebral Cortex, vol. 11, no. 12, pp. 1136–1143, 2001.
- A. M. Owen, J. Doyon, A. Dagher, A. Sadikot, and A. C. Evans, “Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions,” Brain, vol. 121, no. 5, pp. 949–965, 1998.
- A. Dagher, A. M. Owen, H. Boecker, and D. J. Brooks, “The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease,” Brain, vol. 124, no. 5, pp. 1020–1032, 2001.
- R. M. Marié, L. Barré, B. Dupuy, F. Viader, G. Defer, and J. C. Baron, “Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease,” Neuroscience Letters, vol. 260, no. 2, pp. 77–80, 1999.
- A. Brück, R. Portin, A. Lindell et al., “Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus,” Neuroscience Letters, vol. 311, no. 2, pp. 81–84, 2001.
- A. M. Owen, A. C. Roberts, J. R. Hodges, B. A. Summers, C. E. Polkey, and T. W. Robbins, “Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease,” Brain, vol. 116, no. 5, pp. 1159–1175, 1993.
- S. P. Woods and A. I. Tröster, “Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease,” Journal of the International Neuropsychological Society, vol. 9, no. 1, pp. 17–24, 2003.
- J. S. Rakshi, T. Uema, K. Ito et al., “Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]dopa-PET study,” Brain, vol. 122, no. 9, pp. 1637–1650, 1999.
- V. Kaasinen, E. Nurmi, A. Brück et al., “Increased frontal [18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex,” Brain, vol. 124, no. 6, pp. 1125–1130, 2001.
- O. Monchi, M. Petrides, B. Mejia-Constain, and A. P. Strafella, “Cortical activity in Parkinson's disease during executive processing depends on striatal involvement,” Brain, vol. 130, no. 1, pp. 233–244, 2007.
- A. M. Owen, “Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry,” Neuroscientist, vol. 10, no. 6, pp. 525–537, 2004.
- C. Huang, P. Mattis, C. Tang, K. Perrine, M. Carbon, and D. Eidelberg, “Metabolic brain networks associated with cognitive function in Parkinson's disease,” NeuroImage, vol. 34, no. 2, pp. 714–723, 2007.
- R. Cools, R. A. Barker, B. J. Sahakian, and T. W. Robbins, “L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease,” Neuropsychologia, vol. 41, no. 11, pp. 1431–1441, 2003.
- S. Lammel, A. Hetzel, O. Häckel, I. Jones, B. Liss, and J. Roeper, “Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system,” Neuron, vol. 57, no. 5, pp. 760–773, 2008.
- T. Sawaguchi, “The role of D1-dopamine receptors in working memory-guided movements mediated by frontal cortical areas,” Parkinsonism and Related Disorders, vol. 7, no. 1, pp. 9–19, 2000.
- M. J. Frank, L. C. Seeberger, and R. C. O'Reilly, “By carrot or by stick: cognitive reinforcement learning in Parkinsonism,” Science, vol. 306, no. 5703, pp. 1940–1943, 2004.
- R. Swainson, R. D. Rogers, B. J. Sahakian, B. A. Summers, C. E. Polkey, and T. W. Robbins, “Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication,” Neuropsychologia, vol. 38, no. 5, pp. 596–612, 2000.
- R. Cools, S. J. Lewis, L. Clark, R. A. Barker, and T. W. Robbins, “L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease,” Neuropsychopharmacology, vol. 32, no. 1, pp. 180–189, 2007.
- R. Cools, A. Miyakawa, M. Sheridan, and M. D'Esposito, “Enhanced frontal function in Parkinson's disease,” Brain, vol. 133, no. 1, pp. 225–233, 2010.
- A. M. Gotham, R. G. Brown, and C. D. Marsden, “Levodopa treatment may benefit or impair “frontal” function in Parkinson's disease,” The Lancet, vol. 2, no. 8513, pp. 970–971, 1986.
- A. M. Gotham, R. G. Brown, and C. D. Marsden, ““Frontal” cognitive function in patients with Parkinson's disease “on” and “off” levodopa,” Brain, vol. 111, no. 2, pp. 299–321, 1988.
- L. Ishihara and C. Brayne, “A systematic review of depression and mental illness preceding Parkinson's disease,” Acta Neurologica Scandinavica, vol. 113, no. 4, pp. 211–220, 2006.
- S. Ishii, N. Weintraub, and J. R. Mervis, “Apathy: a common psychiatric syndrome in the elderly,” Journal of the American Medical Directors Association, vol. 10, no. 6, pp. 381–393, 2009.
- R. S. Marin, “Apathy: a neuropsychiatric syndrome,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 3, no. 3, pp. 243–254, 1991.
- R. S. Marin, R. C. Biedrzycki, and S. Firinciogullari, “Reliability and validity of the apathy evaluation scale,” Psychiatry Research, vol. 38, no. 2, pp. 143–162, 1991.
- R. Hoehn-Saric, J. R. Lipsey, and D. R. McLeod, “Apathy and indifference in patients on fluvoxamine and fluoxetine,” Journal of Clinical Psychopharmacology, vol. 10, no. 5, pp. 343–345, 1990.
- N. Wongpakaran, R. van Reekum, T. Wongpakaran, and D. Clarke, “Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study,” Annals of General Psychiatry, vol. 6, article 7, 2007.
- P. Remy, M. Doder, A. Lees, N. Turjanski, and D. Brooks, “Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system,” Brain, vol. 128, no. 6, pp. 1314–1322, 2005.
- H. A. Ring, C. J. Bench, M. R. Trimble, D. J. Brooks, R. S. Frackowiak, and R. J. Dolan, “Depression in Parkinson's disease. A positron emission study,” British Journal of Psychiatry, vol. 165, pp. 333–339, 1994.
- K. J. Black, T. Hershey, J. M. Hartlein, J. L. Carl, and J. S. Perlmutter, “Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease,” Neuropsychopharmacology, vol. 30, no. 3, pp. 590–601, 2005.
- H. S. Mayberg, S. K. Brannan, R. K. Mahurin et al., “Cingulate function in depression: a potential predictor of treatment response,” NeuroReport, vol. 8, no. 4, pp. 1057–1061, 1997.
- H. S. Mayberg, M. Liotti, S. K. Brannan et al., “Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness,” American Journal of Psychiatry, vol. 156, no. 5, pp. 675–682, 1999.
- H. S. Mayberg, A. M. Lozano, V. Voon et al., “Deep brain stimulation for treatment-resistant depression,” Neuron, vol. 45, no. 5, pp. 651–660, 2005.
- G. A. Marshall, L. A. Fairbanks, S. Tekin, H. V. Vinters, and J. L. Cummings, “Neuropathologic correlates of apathy in Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 21, no. 3, pp. 144–147, 2006.
- S. Tekin, M. S. Mega, D. M. Masterman et al., “Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease,” Annals of Neurology, vol. 49, no. 3, pp. 355–361, 2001.
- G. A. Marshall, L. Monserratt, D. Harwood, M. Mandelkern, J. L. Cummings, and D. L. Sultzer, “Positron emission tomography metabolic correlates of apathy in Alzheimer disease,” Archives of Neurology, vol. 64, no. 7, pp. 1015–1020, 2007.
- J. S. Reijnders, B. Scholtissen, W. E. Weber, P. Aalten, F. R. Verhey, and A. F. Leentjens, “Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry,” Movement Disorders, vol. 25, no. 14, pp. 2318–2325, 2010.
- K. Strecker, F. Wegner, S. Hesse et al., “Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter,” Journal of Neurology, vol. 258, pp. 19–26, 2011.
- D. Weintraub, K. H. Morales, P. J. Moberg et al., “Antidepressant studies in Parkinson's disease: a review and meta-analysis,” Movement Disorders, vol. 20, no. 9, pp. 1161–1169, 2005.
- D. Weintraub, S. Mavandadi, E. Mamikonyan et al., “Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease,” Neurology, vol. 75, no. 5, pp. 448–455, 2010.
- R. Ventura, S. Cabib, and S. Puglisi-Allegra, “Genetic susceptibility of mesocortical dopamine to stress determines liability to inhibition of mesoaccumbens dopamine and to behavioral 'despair' in a mouse model of depression,” Neuroscience, vol. 115, no. 4, pp. 999–1007, 2002.
- I. Ferrer, “Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease,” Parkinson's Disease, vol. 2011, Article ID 708404, 13 pages, 2011.
- R. Adolphs, “Fear, faces, and the human amygdala,” Current Opinion in Neurobiology, vol. 18, no. 2, pp. 166–172, 2008.
- K. F. Pedersen, G. Alves, K. Brønnick, D. Aarsland, O. B. Tysnes, and J. P. Larsen, “Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian parkWest study,” Journal of Neurology, vol. 257, no. 2, pp. 217–223, 2010.
- C. Brefel-Courbon, P. Payoux, C. Thalamas et al., “Effects of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study,” Movement Disorders, vol. 20, no. 12, pp. 1557–1563, 2005.
- N. Altier and J. Stewart, “The role of dopamine in the nucleus accumbens in analgesia,” Life Sciences, vol. 65, no. 22, pp. 2269–2287, 1999.
- D. J. Scott, M. M. Heitzeg, R. A. Koeppe, C. S. Stohler, and J. K. Zubieta, “Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity,” Journal of Neuroscience, vol. 26, no. 42, pp. 10789–10795, 2006.
- G. Schifitto, J. H. Friedman, D. Oakes et al., “Fatigue in levodopa-naïve subjects with Parkinson disease,” Neurology, vol. 71, no. 7, pp. 481–485, 2008.
- J. S. Lou, G. Kearns, B. Oken, G. Sexton, and J. Nutt, “Exacerbated physical fatigue and mental fatigue in Parkinson's disease,” Movement Disorders, vol. 16, no. 2, pp. 190–196, 2001.
- N. Pavese, V. Metta, S. K. Bose, K. R. Chaudhuri, and D. J. Brooks, “Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction,” Brain, vol. 133, no. 11, pp. 3434–3443, 2010.
- G. Giovannoni, J. D. O'Sullivan, K. Turner, A. J. Manson, and A. J. Lees, “Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 4, pp. 423–428, 2000.
- D. Weintraub, J. Koester, M. N. Potenza et al., “Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients,” Archives of Neurology, vol. 67, no. 5, pp. 589–595, 2010.
- A. H. Evans, N. Pavese, A. D. Lawrence et al., “Compulsive drug use linked to sensitized ventral striatal dopamine transmission,” Annals of Neurology, vol. 59, no. 5, pp. 852–858, 2006.
- T. D. Steeves, J. Miyasaki, M. Zurowski et al., “Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study,” Brain, vol. 132, no. 5, pp. 1376–1385, 2009.
- R. Cilia, C. Siri, G. Marotta et al., “Functional abnormalities underlying pathological gambling in parkinson disease,” Archives of Neurology, vol. 65, no. 12, pp. 1604–1611, 2008.
- W. Schultz, “Getting formal with dopamine and reward,” Neuron, vol. 36, no. 2, pp. 241–263, 2002.
- D. Denys, N. van der Wee, J. Janssen, F. De Geus, and H. G. M. Westenberg, “Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder,” Biological Psychiatry, vol. 55, no. 10, pp. 1041–1045, 2004.
- D. Perani, V. Garibotto, A. Gorini et al., “In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder,” NeuroImage, vol. 42, no. 1, part 3, pp. 306–314, 2008.
- H. C. Breiter and S. L. Rauch, “Functional MRI and the study of OCD: from symptom provocation to cognitive-behavioral probes of cortico-striatal systems and the amygdala,” NeuroImage, vol. 4, no. 3, pp. S127–S138, 1996.
- C. M. Adler, P. McDonough-Ryan, K. W. Sax, S. K. Holland, S. Arndt, and S. M. Strakowski, “fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder,” Journal of Psychiatric Research, vol. 34, no. 4-5, pp. 317–324, 2000.
- E. M. Tricomi, M. R. Delgado, and J. A. Fiez, “Modulation of caudate activity by action contingency,” Neuron, vol. 41, no. 2, pp. 281–292, 2004.
- V. Voon, M. Sohr, A. E. Lang et al., “Impulse control disorders in parkinson disease: a multicenter case-control study,” Annals of Neurology, vol. 69, no. 6, pp. 986–996, 2011.
- R. de la Fuente-Fernández, J. Q. Lu, V. Sossi et al., “Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover,” Annals of Neurology, vol. 49, no. 3, pp. 298–303, 2001.
- A. Nagano-Saito, Y. Washimi, Y. Arahata et al., “Visual hallucination in Parkinson's disease with FDG PET,” Movement Disorders, vol. 19, no. 7, pp. 801–806, 2004.
- H. Boecker, A. O. Ceballos-Baumann, D. Volk, B. Conrad, H. Forstl, and P. Haussermann, “Metabolic alterations in patients with Parkinson disease and visual hallucinations,” Archives of Neurology, vol. 64, no. 7, pp. 984–988, 2007.
- N. I. Bohnen, D. I. Kaufer, L. S. Ivanco et al., “Cortical cholinergic function is more severely affected in Parkinsonian dementia than in alzheimer disease: an in vivo positron emission tomographic study,” Archives of Neurology, vol. 60, no. 12, pp. 1745–1748, 2003.
- R. Hilker, A. V. Thomas, J. C. Klein et al., “Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways,” Neurology, vol. 65, no. 11, pp. 1716–1722, 2005.
- P. Edison, C. C. Rowe, J. O. Rinne et al., “Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 12, pp. 1331–1338, 2008.
- S. N. Gomperts, D. M. Rentz, E. Moran et al., “Imaging amyloid deposition in lewy body diseases,” Neurology, vol. 71, no. 12, pp. 903–910, 2008.
- T. Soulas, J. M. Gurruchaga, S. Palfi, P. Cesaro, J. P. Nguyen, and G. Fénelon, “Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 8, pp. 952–954, 2008.
- V. Voon, P. Krack, A. E. Lang et al., “A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease,” Brain, vol. 131, no. 10, pp. 2720–2728, 2008.
- A. F. Arnsten, “Catecholamine modulation of prefrontal cortical cognitive function,” Trends in Cognitive Sciences, vol. 2, no. 11, pp. 436–447, 1998.
- L. C. Butterfield, C. R. Cimino, L. E. Oelke, R. A. Hauser, and J. Sanchez-Ramos, “The independent influence of apathy and depression on cognitive functioning in Parkinson's disease,” Neuropsychology, vol. 24, no. 6, pp. 721–730, 2010.
- R. L. Drijgers, K. Dujardin, J. S. Reijnders, L. Defebvre, and A. F. Leentjens, “Validation of diagnostic criteria for apathy in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 16, no. 10, pp. 656–660, 2010.
- R. G. Brown, A. Dittner, L. Findley, and S. C. Wessely, “The Parkinson fatigue scale,” Parkinsonism and Related Disorders, vol. 11, no. 1, pp. 49–55, 2005.
Copyright © 2012 Raúl de la Fuente-Fernández. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.